[A21-59] Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 20.10.2021
Commission awarded on 03.05.2021 by the Federal Joint Committee (G-BA).
Adults with treatment-naive advanced renal cell carcinoma
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2021-08-02.